Jump to content

2C-B: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

26 May 2026

22 May 2026

  • curprev 16:4716:47, 22 May 2026 MDElliottMD talk contribs 18,269 bytes +27 Link legal-status field to the USLegal: namespace [automatically checked]
  • curprev 03:0103:01, 22 May 2026 MDElliottMD talk contribs 18,242 bytes 0 Repoint receptor links to the new Receptor: namespace [automatically checked]
  • curprev 02:5702:57, 22 May 2026 MDElliottMD talk contribs 18,242 bytes −78 Repoint CYP2D6/CYP3A4 links to the new Enzyme: namespace [automatically checked]
  • curprev 01:4001:40, 22 May 2026 MDElliottMD talk contribs 18,320 bytes +480 2C-B final link addendum (web-claude, consolidated): merge new links onto the citation-corrected page (5-HT2A/2C/2B receptors, monoamine transporter, Schedule I, Controlled Substances Act, Convention on Psychotropic Substances, Medicines Control Council, Ann Shulgin, Empathogens); psychostimulants house-term fix; propagate the lithium clinical correction into the interactions field [automatically checked]
  • curprev 00:0900:09, 22 May 2026 MDElliottMD talk contribs 17,840 bytes +163 2C-B harm-reduction: clinical correction (pharmacist-claude) - lithium moved out of the serotonin-syndrome list into its own sentence (lithium + psychedelic risk is seizures/severe reactions, not serotonin syndrome) [automatically checked]

21 May 2026

15 May 2026

14 May 2026

13 May 2026